CytomX Therapeutics Inc (CTMX) - Net Assets
Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has net assets worth $319.94 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($359.36 Million) and total liabilities ($39.41 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CTMX tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $319.94 Million |
| % of Total Assets | 89.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | 10.77% |
| 10-Year Change | 26.16% |
| Growth Volatility | 87.56 |
CytomX Therapeutics Inc - Net Assets Trend (2013–2025)
This chart illustrates how CytomX Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See CTMX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for CytomX Therapeutics Inc (2013–2025)
The table below shows the annual net assets of CytomX Therapeutics Inc from 2013 to 2025. For live valuation and market cap data, see CTMX stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $99.01 Million | +21812.28% |
| 2024-12-31 | $-456.00K | +99.04% |
| 2023-12-31 | $-47.45 Million | +44.67% |
| 2022-12-31 | $-85.75 Million | -195.94% |
| 2021-12-31 | $89.38 Million | +1249.72% |
| 2020-12-31 | $-7.77 Million | -115.21% |
| 2019-12-31 | $51.11 Million | -60.95% |
| 2018-12-31 | $130.88 Million | +87.25% |
| 2017-12-31 | $69.90 Million | -10.94% |
| 2016-12-31 | $78.48 Million | -37.75% |
| 2015-12-31 | $126.07 Million | +260.51% |
| 2014-12-31 | $-78.54 Million | -77.38% |
| 2013-12-31 | $-44.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CytomX Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 66806800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Comprehensive Income | $111.00K | 0.11% |
| Other Components | $810.84 Million | 818.97% |
| Total Equity | $99.01 Million | 100.00% |
CytomX Therapeutics Inc Competitors by Market Cap
The table below lists competitors of CytomX Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Chippacking Technology Co. Ltd. A
SHG:688216
|
$644.46 Million |
|
Bomesc Offshore Engineering Co
SHG:603727
|
$644.75 Million |
|
mobilezone ag
SW:MOZN
|
$644.79 Million |
|
Shaanxi Kanghui Pharm Co Ltd
SHG:603139
|
$644.99 Million |
|
DCB Bank Limited
NSE:DCBBANK
|
$644.37 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
$644.31 Million |
|
Beibu Gulf Tourism Corp Ltd
SHG:603869
|
$644.24 Million |
|
Patrizia AG
XETRA:PAT
|
$644.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CytomX Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -456,000 to 99,008,000, a change of 99,464,000.
- Net loss of 17,368,000 reduced equity.
- Dividend payments of 3,002,000 reduced retained earnings.
- New share issuances of 109,635,000 increased equity.
- Other comprehensive income increased equity by 84,000.
- Other factors increased equity by 10,115,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.37 Million | -17.54% |
| Dividends Paid | $3.00 Million | -3.03% |
| Share Issuances | $109.64 Million | +110.73% |
| Other Comprehensive Income | $84.00K | +0.08% |
| Other Changes | $10.12 Million | +10.22% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares CytomX Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-44.79 | $2.96 | x |
| 2014-12-31 | $-2.25 | $2.96 | x |
| 2015-12-31 | $3.55 | $2.96 | x |
| 2016-12-31 | $2.17 | $2.96 | x |
| 2017-12-31 | $1.88 | $2.96 | x |
| 2018-12-31 | $3.14 | $2.96 | x |
| 2019-12-31 | $1.13 | $2.96 | x |
| 2020-12-31 | $-0.17 | $2.96 | x |
| 2021-12-31 | $1.39 | $2.96 | x |
| 2022-12-31 | $-1.30 | $2.96 | x |
| 2023-12-31 | $-0.64 | $2.96 | x |
| 2024-12-31 | $-0.01 | $2.96 | x |
| 2025-12-31 | $0.72 | $2.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CytomX Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.79%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.53x
- Recent ROE (-17.54%) is above the historical average (-41.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -1705.29% | 0.06x | 0.00x | $-10.72 Million |
| 2014 | 0.00% | -597.01% | 0.07x | 0.00x | $-22.46 Million |
| 2015 | -28.06% | -458.69% | 0.04x | 1.56x | $-47.98 Million |
| 2016 | -75.05% | -391.54% | 0.08x | 2.54x | $-66.75 Million |
| 2017 | -61.66% | -60.17% | 0.18x | 5.69x | $-50.09 Million |
| 2018 | -64.64% | -142.19% | 0.13x | 3.49x | $-97.69 Million |
| 2019 | -200.02% | -177.84% | 0.17x | 6.68x | $-107.35 Million |
| 2020 | 0.00% | -94.73% | 0.19x | 0.00x | $-64.04 Million |
| 2021 | -90.23% | -115.92% | 0.20x | 3.80x | $-89.59 Million |
| 2022 | 0.00% | -183.02% | 0.20x | 0.00x | $-88.72 Million |
| 2023 | 0.00% | -0.56% | 0.50x | 0.00x | $4.18 Million |
| 2024 | 0.00% | 23.08% | 1.15x | 0.00x | $31.91 Million |
| 2025 | -17.54% | -22.79% | 0.50x | 1.53x | $-27.27 Million |
Industry Comparison
This section compares CytomX Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CytomX Therapeutics Inc (CTMX) | $319.94 Million | 0.00% | 0.12x | $644.40 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell… Read more